[1] van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis , 2014, 9(1): 51-63.
[2] Sobreira E, Pires RF, Cizmarik M, Grabowski GA. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest-of-the-world. Mol Genet Metab , 2007, 90(1): 81-86.
[3] Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA , 1999, 281(3): 249-254.
[4] Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet , 2008, 372(9645): 1263-1271.
[5] Chan A, Holleran WM, Ferguson T, Crumrine D, Goker-Alpan O, Schiffmann R, Tayebi N, Ginns EI, Elias PM, Sidransky E. Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications. Mol Genet Metab , 2011, 104(4): 631-636.
[6] Elstein D, Abrahamov A, Altarescu G, Zimran A. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy. Blood Cells Mol Dis , 2013, 50(2): 140.
[7] Bendikov-Bar I, Ron I, Filocamo M, Horowitz M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis , 2011, 46(1): 4-10.
[8] Bendikov-Bar I, Horowitz M. Gaucher disease paradigm: from ERAD to comorbidity. Hum Mutat , 2012, 33(10): 1398-1407.
[9] Yang CZ, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang ZP. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci USA , 2013, 110(3): 966-971.
[10] Wang F, Chou A, Segatori L. Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chem Biol , 2011, 18(6): 766-776.
[11] Tan YL, Genereux JC, Pankow S, Aerts JMFG, Yates JRIII, Kelly JW. ERdj3 Is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to gaucher's disease. Chem Biol , 2014, 21(8): 967-976.
[12] Tamargo RJ, Velayati A, Goldin E, Sidransky E. The role of saposin C in Gaucher disease. Mol Genet Metab , 2012, 106(3): 257-263.
[13] Velayati A, DePaolo J, Gupta N, Choi JH, Moaven N, Westbroek W, Goker-Alpan O, Goldin E, Stubblefield BK, Kolodny E, Tayebi N, Sidransky E. A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat , 2011, 32(11): 1232-1238.
[14] Alfonso P, Pampin S, García-Rodríguez B, Tejedor T, Domínguez C, Rodríguez-Rey JC, Giraldo P, Pocoví M. Characterization of the c. (-203)A>G variant in the glucocerebrosidase gene and its association with phenotype in Gaucher disease. Clin Chim Acta , 2011, 412(3-4): 365-369.
[15] Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neurodegener Dis , 2012, 10(1-4): 195-202.
[16] Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab , 2013, 108(1): 56-64.
[17] Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program , 2012, 2012(1): 13-18.
[18] Franco M, Collec E, Connes P, van den Akker E, de Villemeur T B, Belmatoug N, von Lindern M, Ameziane N, Hermine O, Colin Y, Le Van Kim C, Mignot C. Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood , 2013, 121(3): 546-555.
[19] Liu J, Halene S, Yang M, Iqbal J, Yang RH, Mehal WZ, Chuang WL, Jain D, Yuen T, Sun L, Zaidi M, Mistry PK. Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci USA , 2012, 109(25): 10018-10023.
[20] Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao HY, Lin AP, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, B
